FDA proposes to ease rules on off-label drug use

02/17/2008 | NYTimes.com

The FDA on Friday recommended new guidelines that would let drug and medical-device makers supply doctors with copies of journal articles on off-label uses of their products. Advocates say the proposal would give physicians access to credible scientific data that could potentially save lives, while critics argue that allowing such a practice could compromise patient safety and result in unreliable research on the benefits of drugs and devices.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC